Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Haemonetics Corp (NYSE: HAE) closed at $75.73 down -3.92% from its previous closing price of $78.82. In other words, the price has decreased by -$3.92 from its previous closing price. On the day, 0.89 million shares were traded. HAE stock price reached its highest trading level at $78.82 during the session, while it also had its lowest trading level at $75.28.
Ratios:
For a deeper understanding of Haemonetics Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.96 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.84. For the most recent quarter (mrq), Quick Ratio is recorded 1.03 and its Current Ratio is at 1.64. In the meantime, Its Debt-to-Equity ratio is 1.44 whereas as Long-Term Debt/Eq ratio is at 1.08.
On December 11, 2025, Citigroup Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $88.
Raymond James Downgraded its Strong Buy to Outperform on August 11, 2025, while the target price for the stock was maintained at $78.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 10 ’25 when KROLL MARK W bought 1,400 shares for $70.56 per share. The transaction valued at 98,784 led to the insider holds 24,757 shares of the business.
Llorens Josep bought 18,630 shares of HAE for $1,396,132 on Jun 26 ’25. On Jun 12 ’25, another insider, Strong Stewart W, who serves as the Former Officer of the company, bought 708 shares for $71.46 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 3648463872 and an Enterprise Value of 4472983552. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.09, and their Forward P/E ratio for the next fiscal year is 13.81. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.37. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.67 while its Price-to-Book (P/B) ratio in mrq is 4.17. Its current Enterprise Value per Revenue stands at 3.369 whereas that against EBITDA is 12.414.
Stock Price History:
The Beta on a monthly basis for HAE is 0.28, which has changed by 0.0719434 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, HAE has reached a high of $87.32, while it has fallen to a 52-week low of $47.31. The 50-Day Moving Average of the stock is -2.38%, while the 200-Day Moving Average is calculated to be 15.08%.
Shares Statistics:
For the past three months, HAE has traded an average of 833.25K shares per day and 594020 over the past ten days. A total of 46.75M shares are outstanding, with a floating share count of 46.05M. Insiders hold about 1.62% of the company’s shares, while institutions hold 110.93% stake in the company. Shares short for HAE as of 1767139200 were 3491564 with a Short Ratio of 4.19, compared to 1764288000 on 3621526. Therefore, it implies a Short% of Shares Outstanding of 3491564 and a Short% of Float of 10.01.
Earnings Estimates
. The current assessment of Haemonetics Corp (HAE) involves the perspectives of 11.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $1.3, with high estimates of $1.34 and low estimates of $1.25.
Analysts are recommending an EPS of between $4.95 and $4.85 for the fiscal current year, implying an average EPS of $4.91. EPS for the following year is $5.47, with 10.0 analysts recommending between $5.62 and $5.3.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $331.9M this quarter.It ranges from a high estimate of $336M to a low estimate of $327.7M. As of. The current estimate, Haemonetics Corp’s year-ago sales were $348.54MFor the next quarter, 11 analysts are estimating revenue of $337.42M. There is a high estimate of $343.6M for the next quarter, whereas the lowest estimate is $332.77M.
A total of 11 analysts have provided revenue estimates for HAE’s current fiscal year. The highest revenue estimate was $1.32B, while the lowest revenue estimate was $1.31B, resulting in an average revenue estimate of $1.32B. In the same quarter a year ago, actual revenue was $1.36BBased on 10 analysts’ estimates, the company’s revenue will be $1.4B in the next fiscal year. The high estimate is $1.42B and the low estimate is $1.37B.
